ACTRN12621000692831已完成未知
A prospective, multi-centre phase I/II trial investigating the safety and patient-reported outcomes of patients with acute uncomplicated diverticulitis through rpavirtual
Surgical Outcomes Research Centre, Royal Prince Alfred Hospital0 个研究点目标入组 50 人开始时间: 2021年6月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •To be considered for this trial, patients must:
- •1.be diagnosed with CT-proven acute uncomplicated diverticulitis;
- •2.have access to a telephone, computer, or smart device with videoconferencing capabilities;
- •3.reside within the SLHD catchment area during the time of admission to iCAD.
排除标准
- •The following patient scenarios are excluded:
- •1.generalised peritonitis
- •2.temperature > 38°C
- •3.heart rate > 100, or evidence of haemodynamic instability
- •4.white cell count (WCC) >20, C reactive protein (CRP) >150, or acute renal impairment
- •5.other signs or symptoms concerning for systemic sepsis
- •6.pregnancy
- •7.immunosuppressed
- •8.cognitive impairment
研究者
相似试验
进行中（未招募）
2 期
A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed aggressive LymphomaC83.3Diffuse large B-cell lymphomaDRKS00023793niversitätsmedizin der Johannes Gutenberg-Universität Mainz26
进行中（未招募）
1 期
A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma.Malignant B-cell lymphomaMedDRA version: 21.0Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002373-59-DEniversity Medical Center of the Johannes Gutenberg University Mainz64
进行中（未招募）
不适用
A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple MyelomaMultiple Myeloma (Salmon-Durie stage II or III, Relapsed or refractory disease after failure of two or more treatment regimens)MedDRA version: 8.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2006-002675-41-DEniversitaetsklinikum Schleswig-Holstein
进行中（未招募）
1 期
A study to investigate the safety and antiemetic efficacy of 2 agents: Akynzeo® plus dexamethasone in patients receiving simultaneously radiotherapy and chemotherapy with weekly cisplatin for at least five weeks.Eligible patients will have a diagnosis of cervical cancer, and be scheduled to receive fractionated radiotherapy and concomitant weekly cisplatin at a dose of = 40 mg/m2 for at least five weeks. Patients must be naïve to both radiotherapy and chemotherapy.EUCTR2017-004031-37-DKDepartment of oncology, Odense University Hospital80
进行中（未招募）
1 期
Clinical trial conducted to evaluate the effectiveness of a combination of drugs called venetoclax and rituximab adapted to the state of minimal residual disease in patients with untreated chronic lymphocytic leukemiaEUCTR2019-004613-14-PLPOLISH ADULT LEUKEMIA GROUP103